Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Clinician,Recombinant Zoster Vaccine,Catch-up programme due to COVID-19 pandemic disruption,Recombinant Zoster Vaccine (Shingrix),Options for investment,Community and Hospital,
